Effects of Liraglutide Monotherapy on Beta Cell Function and Pancreatic Enzymes Compared with Metformin in Japanese Overweight/Obese Patients with Type 2 Diabetes Mellitus: A Subpopulation Analysis of the KIND-LM Randomized Trial.

Tanaka K, Saisho Y, Manesso E, Tanaka M, Meguro S, Irie J, Sugiura H, Kawai T, Jinzaki M, Cobelli C, Itoh H

Clinical drug investigation1 Oct 2015Cited by 15 (Europe PMC)

PMID26369653DOI10.1007/s40261-015-0331-5PepBankPUB-26369653

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study11

11 results from studies that gave the peptide. 11 results from people.

01HumanRandomized controlled trialEfficacy outcome
In overweight or obese Japanese patients with type 2 diabetes, the change in HbA1c at week 24 was comparable between liraglutide and metformin.
In plain wordsIn Japanese adults with overweight or obesity and type 2 diabetes, HbA1c changed about the same with liraglutide and metformin.
Peptide
Liraglutide
Outcome
No significant changeHbA1c change at week 24
Study
n = 20
Comparator
Metformin
Analysis
Exploratory
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · subcutaneous · 24 weeksAs given in this study (human).
Source sentences
Summary
Changes in glycemic parameters such as glycated hemoglobulin (HbA1c), glycated albumin and 1,5-anhydroglucitol at week 24 were comparable between the groups.
2 context sentences(design, population, supporting numbers)
Summary · context
n = 20, 10 in oral metformin group and 10 in subcutaneous liraglutide group)
Summary · context
The patients were treated with either metformin or liraglutide throughout the 24-week study period.
Report a problemFND-2636965301
02HumanRandomized controlled trialEfficacy outcome
In overweight or obese Japanese patients with type 2 diabetes, the change in glycated albumin at week 24 was comparable between liraglutide and metformin.
In plain wordsIn Japanese adults with overweight or obesity and type 2 diabetes, glycated albumin changed about the same with liraglutide and metformin.
Peptide
Liraglutide
Outcome
No significant changeGlycated albumin change at week 24
Study
n = 20
Comparator
Metformin
Analysis
Exploratory
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · subcutaneous · 24 weeksAs given in this study (human).
Source sentences
Summary
Changes in glycemic parameters such as glycated hemoglobulin (HbA1c), glycated albumin and 1,5-anhydroglucitol at week 24 were comparable between the groups.
2 context sentences(design, population, supporting numbers)
Summary · context
n = 20, 10 in oral metformin group and 10 in subcutaneous liraglutide group)
Summary · context
The patients were treated with either metformin or liraglutide throughout the 24-week study period.
Report a problemFND-2636965302
03HumanRandomized controlled trialEfficacy outcome
In overweight or obese Japanese patients with type 2 diabetes, the change in 1,5-anhydroglucitol at week 24 was comparable between liraglutide and metformin.
In plain wordsIn Japanese adults with overweight or obesity and type 2 diabetes, 1,5-anhydroglucitol changed about the same with liraglutide and metformin.
Peptide
Liraglutide
Outcome
No significant change1,5-anhydroglucitol change at week 24
Study
n = 20
Comparator
Metformin
Analysis
Exploratory
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · subcutaneous · 24 weeksAs given in this study (human).
Source sentences
Summary
Changes in glycemic parameters such as glycated hemoglobulin (HbA1c), glycated albumin and 1,5-anhydroglucitol at week 24 were comparable between the groups.
2 context sentences(design, population, supporting numbers)
Summary · context
n = 20, 10 in oral metformin group and 10 in subcutaneous liraglutide group)
Summary · context
The patients were treated with either metformin or liraglutide throughout the 24-week study period.
Report a problemFND-2636965303
04HumanRandomized controlled trialEfficacy outcome
In overweight or obese Japanese patients with type 2 diabetes, static-phase beta cell responsiveness increased significantly at week 24 with liraglutide but not with metformin.
In plain wordsIn Japanese adults with overweight or obesity and type 2 diabetes, liraglutide improved beta cell response, but metformin did not.
Peptide
Liraglutide
Outcome
IncreaseStatic-phase beta cell responsiveness
Study
n = 20
Comparator
Metformin
Analysis
Exploratory
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · subcutaneous · 24 weeksAs given in this study (human).
Source sentences
Summary
An oral minimal model based on MTT revealed that static-phase beta cell responsiveness (Φ s) and static-phase disposition index were significantly increased at week 24 in the liraglutide group but not in the metformin group.
2 context sentences(design, population, supporting numbers)
Summary · context
n = 20, 10 in oral metformin group and 10 in subcutaneous liraglutide group)
Summary · context
The patients were treated with either metformin or liraglutide throughout the 24-week study period.
Report a problemFND-2636965304
05HumanRandomized controlled trialEfficacy outcome
In overweight or obese Japanese patients with type 2 diabetes, the static-phase disposition index increased significantly at week 24 with liraglutide but not with metformin.
In plain wordsIn Japanese adults with overweight or obesity and type 2 diabetes, liraglutide raised the disposition index, but metformin did not.
Peptide
Liraglutide
Outcome
IncreaseStatic-phase disposition index
Study
n = 20
Comparator
Metformin
Analysis
Exploratory
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · subcutaneous · 24 weeksAs given in this study (human).
Source sentences
Summary
An oral minimal model based on MTT revealed that static-phase beta cell responsiveness (Φ s) and static-phase disposition index were significantly increased at week 24 in the liraglutide group but not in the metformin group.
2 context sentences(design, population, supporting numbers)
Summary · context
n = 20, 10 in oral metformin group and 10 in subcutaneous liraglutide group)
Summary · context
The patients were treated with either metformin or liraglutide throughout the 24-week study period.
Report a problemFND-2636965305
06HumanRandomized controlled trialEfficacy outcome
In overweight or obese Japanese patients with type 2 diabetes, fat distribution did not change significantly at week 24 in either group.
In plain wordsIn Japanese adults with overweight or obesity and type 2 diabetes, body fat distribution did not change with liraglutide or metformin.
Peptide
Liraglutide
Outcome
No significant changeFat distribution
Study
n = 20
Comparator
Metformin
Analysis
Exploratory
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated · subcutaneous · 24 weeksAs given in this study (human).
Source sentences
Summary
There was no significant change in fat distribution as well as body weight at week 24 in either group.
2 context sentences(design, population, supporting numbers)
Summary · context
n = 20, 10 in oral metformin group and 10 in subcutaneous liraglutide group)
Summary · context
The patients were treated with either metformin or liraglutide throughout the 24-week study period.
Report a problemFND-2636965306
07HumanRandomized controlled trialEfficacy outcome
In overweight or obese Japanese patients with type 2 diabetes, body weight did not change significantly at week 24 in either group.
In plain wordsIn Japanese adults with overweight or obesity and type 2 diabetes, body weight did not change with liraglutide or metformin.
Peptide
Liraglutide
Outcome
No significant changeBody weight at week 24
Study
n = 20
Comparator
Metformin
Analysis
Exploratory
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated · subcutaneous · 24 weeksAs given in this study (human).
Source sentences
Summary
There was no significant change in fat distribution as well as body weight at week 24 in either group.
2 context sentences(design, population, supporting numbers)
Summary · context
n = 20, 10 in oral metformin group and 10 in subcutaneous liraglutide group)
Summary · context
The patients were treated with either metformin or liraglutide throughout the 24-week study period.
Report a problemFND-2636965307
08HumanRandomized controlled trialSafety outcome
In overweight or obese Japanese patients with type 2 diabetes, serum amylase increased modestly but significantly with liraglutide.
In plain wordsIn Japanese adults with overweight or obesity and type 2 diabetes, liraglutide modestly raised blood amylase, a pancreatic enzyme.
Peptide
Liraglutide
Outcome
IncreaseSerum amylase
Study
n = 10
Comparator
Baseline
Analysis
Exploratory
Outcome group
Adverse events · Gastrointestinal
Studied dose
Dose not stated · subcutaneous · 24 weeksAs given in this study (human).
Source sentences
Summary
Serum amylase and lipase levels modestly but significantly increased in the liraglutide group during the study
2 context sentences(design, population, supporting numbers)
Summary · context
n = 20, 10 in oral metformin group and 10 in subcutaneous liraglutide group)
Summary · context
The patients were treated with either metformin or liraglutide throughout the 24-week study period.
Report a problemFND-2636965308
09HumanRandomized controlled trialSafety outcome
In overweight or obese Japanese patients with type 2 diabetes, serum lipase increased modestly but significantly with liraglutide.
In plain wordsIn Japanese adults with overweight or obesity and type 2 diabetes, liraglutide modestly raised blood lipase, a pancreatic enzyme.
Peptide
Liraglutide
Outcome
IncreaseSerum lipase
Study
n = 10
Comparator
Baseline
Analysis
Exploratory
Outcome group
Adverse events · Gastrointestinal
Studied dose
Dose not stated · subcutaneous · 24 weeksAs given in this study (human).
Source sentences
Summary
Serum amylase and lipase levels modestly but significantly increased in the liraglutide group during the study
2 context sentences(design, population, supporting numbers)
Summary · context
n = 20, 10 in oral metformin group and 10 in subcutaneous liraglutide group)
Summary · context
The patients were treated with either metformin or liraglutide throughout the 24-week study period.
Report a problemFND-2636965309
10HumanRandomized controlled trialSafety outcome
In overweight or obese Japanese patients with type 2 diabetes, no pancreatitis occurred with liraglutide.
In plain wordsIn Japanese adults with overweight or obesity and type 2 diabetes, nobody on liraglutide developed pancreatitis.
Peptide
Liraglutide
Outcome
No significant changePancreatitis incidence
Study
n = 10
Analysis
Exploratory
Outcome group
Adverse events · Gastrointestinal
Studied dose
Dose not stated · subcutaneous · 24 weeksAs given in this study (human).
Source sentences
Summary
there was no incidence of pancreatitis
2 context sentences(design, population, supporting numbers)
Summary · context
n = 20, 10 in oral metformin group and 10 in subcutaneous liraglutide group)
Summary · context
The patients were treated with either metformin or liraglutide throughout the 24-week study period.
Report a problemFND-2636965310
11HumanRandomized controlled trialSafety outcome
In overweight or obese Japanese patients with type 2 diabetes, pancreas volume did not change with liraglutide.
In plain wordsIn Japanese adults with overweight or obesity and type 2 diabetes, liraglutide did not change pancreas size.
Peptide
Liraglutide
Outcome
No significant changePancreas volume
Study
n = 10
Comparator
Baseline
Analysis
Exploratory
Outcome group
Adverse events · Gastrointestinal
Studied dose
Dose not stated · subcutaneous · 24 weeksAs given in this study (human).
Source sentences
Summary
pancreas volume was not changed in the liraglutide group.
2 context sentences(design, population, supporting numbers)
Summary · context
n = 20, 10 in oral metformin group and 10 in subcutaneous liraglutide group)
Summary · context
The patients were treated with either metformin or liraglutide throughout the 24-week study period.
Report a problemFND-2636965311

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
12 Oct 2026, 12:10 UTC
Study results updated
Version 1
9 Oct 2026, 03:05 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.